Community Health Media

Community Health Media
  • 0.0 (0)
  • Medicine

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences. We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcasts

  1. 3d ago

    Drs. Jason Mouabbi, Ruta Rao, & Mark Pegram - Unpacking DESTINY-Breast09 in HER2+ mBC

    A new era in HER2-positive metastatic breast cancer is here.Dr. Jason Mouabbi, Dr. Ruta Rao, and Dr. Mark Pegram break down the groundbreaking DESTINY-Breast09 trial and discuss how trastuzumab deruxtecan (T-DXd) plus pertuzumab is redefining first-line treatment. The conversation explores: Why DB09 may replace the CLEOPATRA standardThe significance of 40+ month median PFSComplete response rates and treatment durabilityManaging ILD, fatigue, nausea, and alopeciaMaintenance therapy strategiesPATINA and HER2CLIMB-05 insightsSequencing after T-DXd progressionWhy “saving your best drug for later” may no longer apply This is a must-watch discussion on the evolving frontline landscape in HER2+ metastatic breast cancer. –Thanks for watching!Our podcasts are also available on: Spotify - https://spotf.fi/chm-podcastAmazon Music - https://amazn.so/chm-podcastApple Podcast - https://podcasts.apple.com/us/podcast...Castbox - https://castbox.fm/vh/6735434Goodpods - https://goodpods.com/profile/chm-111066iHeartRadio - https://iheart.com/podcast/291542082Pocket Casts - https://pca.st/3ncdh11o –Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: Peer to peer interviews, panels & round-tablesCurated live events & conferencesProfessional in-depth content & research updatesInteractive learning modules & webinarsLive & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media

    Drs. Jason Mouabbi, Ruta Rao, & Mark Pegram - Unpacking DESTINY-Breast09 in HER2+ mBC

  2. Jul 7

    Dr. Anne O'Dea & Dr. Mabel Mardones - SERENA-6 & ctDNA-Guided Therapy in mBC

    Can we improve outcomes by changing treatment before radiographic progression occurs? In this in-depth discussion, Dr. Anne O'Dea and Dr. Mabel Mardones explore how the SERENA-6 trial is reshaping the management of HR-positive, HER2-negative metastatic breast cancer through ctDNA-guided treatment decisions and earlier intervention for emerging ESR1 mutations. Topics discussed include: The clinical impact of the SERENA-6 trialUsing ctDNA to detect ESR1 mutations before disease progressionWhen and why to switch endocrine therapyCamizestrant and molecularly guided treatment strategiesIntegrating biomarker monitoring into routine clinical practicePatient communication, monitoring, and quality-of-life considerationsPractical challenges and implementation in the community settingFeaturing expert insights from Dr. Anne O'Dea and Dr. Mabel Mardones on one of the most important advances in precision oncology for HR-positive metastatic breast cancer.Watch the full conversation and subscribe for more expert discussions on the latest clinical evidence shaping cancer care. –Thanks for watching!Our podcasts are also available on: Spotify - ⁠https://spotf.fi/chm-podcast⁠Amazon Music - ⁠https://amazn.so/chm-podcast⁠Apple Podcast - ⁠https://podcasts.apple.com/us/podcast...⁠Castbox - ⁠https://castbox.fm/vh/6735434⁠Goodpods - ⁠https://goodpods.com/profile/chm-111066⁠iHeartRadio - ⁠https://iheart.com/podcast/291542082⁠Pocket Casts - ⁠https://pca.st/3ncdh11o⁠ –Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: Peer to peer interviews, panels & round-tablesCurated live events & conferencesProfessional in-depth content & research updatesInteractive learning modules & webinarsLive & on-demand webcasts & podcastsLearn more about us here - ⁠https://communityhealth.media⁠

    Dr. Anne O'Dea & Dr. Mabel Mardones - SERENA-6 & ctDNA-Guided Therapy in mBC

  3. Jun 26

    Dr. Rena Callahan & Dr. Aditya Bardia - Integrating T-DXd in HER2+ Breast Cancer: DB11, DB05 & DB09

    HER2-positive breast cancer treatment is evolving rapidly. With FDA approvals from DESTINY-Breast11 and DESTINY-Breast05, when should clinicians incorporate trastuzumab deruxtecan (T-DXd) into practice—and how should it be used across early-stage and into metastatic disease? In this in-depth discussion, Dr. Rena Callahan and Dr. Aditya Bardia explore how these landmark studies are changing treatment decisions today across neoadjuvant, adjuvant, and metastatic settings—including the management of residual disease and the optimization of first-line metastatic care.Key topics discussed: How DESTINY-Breast11 is changing neoadjuvant treatment strategiesDESTINY-Breast05 and the role of T-DXd for residual diseaseWhich patients should receive T-DXd versus T-DM1Managing ILD risk and monitoring requirementsTreatment decisions for patients who do not achieve pCRRechallenging T-DXd after recurrenceFirst-line metastatic HER2-positive breast cancer after DESTINY-Breast09Deep responses, complete responses, and long-term outcomesT-DXd versus THP in clinical practicePATINA, HER2CLIMB-05, and evolving maintenance strategiesCNS metastases and the role of HER2-targeted ADCsTreatment holidays, ctDNA monitoring, and personalized care As T-DXd moves into earlier lines of therapy, oncologists are facing new questions around sequencing, toxicity management, and optimizing long-term outcomes. This conversation provides practical insights for both academic and community clinicians navigating this rapidly changing landscape. Subscribe for more expert oncology discussions, breast cancer updates, and clinical trial insights from Community Health Media. –Thanks for watching!Our podcasts are also available on: Spotify - ⁠https://spotf.fi/chm-podcast⁠Amazon Music - ⁠https://amazn.so/chm-podcast⁠Apple Podcast - ⁠https://podcasts.apple.com/us/podcast...⁠Castbox - ⁠https://castbox.fm/vh/6735434⁠Goodpods - ⁠https://goodpods.com/profile/chm-111066⁠iHeartRadio - ⁠https://iheart.com/podcast/291542082⁠Pocket Casts - ⁠https://pca.st/3ncdh11o⁠ –Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: Peer to peer interviews, panels & round-tablesCurated live events & conferencesProfessional in-depth content & research updatesInteractive learning modules & webinarsLive & on-demand webcasts & podcastsLearn more about us here - ⁠https://communityhealth.media⁠

    Dr. Rena Callahan & Dr. Aditya Bardia - Integrating T-DXd in HER2+ Breast Cancer: DB11, DB05 & DB09

  4. Jun 26

    Dr. Neil Iyengar, Dr. Joyce O'Shaughnessy, & Dr. Ana Garrido-Castro - Evolving ADCs in 1L mTNBC

    The first-line treatment landscape for metastatic triple-negative breast cancer is changing rapidly. Dr. Neil Iyengar, Dr. Joyce O'Shaughnessy, and Dr. Ana Garrido-Castro discuss how ADCs are reshaping frontline TNBC care and what the latest clinical evidence means for real-world practice. The conversation explores: The evolution of metastatic TNBC treatmentWhy many patients never reach second-line therapyThe impact of ASCENT and sacituzumab govitecanASCENT-03 and ASCENT-04 trial resultsTROPION-Breast02 and datopotamab deruxtecanThe role of crossover in interpreting overall survivalPFS, OS, and PFS2 as clinical trial endpointsSelecting between SG and Dato-DXdManaging neutropenia, stomatitis, ocular toxicity, and ILDShared decision-making in frontline TNBCWhy using the best therapy first may matter mostThis comprehensive discussion examines the evidence driving ADC use in metastatic TNBC and how clinicians can individualize treatment selection in an increasingly complex therapeutic landscape. Watch now to hear how ADCs are reshaping frontline TNBC care. –Thanks for watching!Our podcasts are also available on: Spotify - ⁠https://spotf.fi/chm-podcast⁠Amazon Music - ⁠https://amazn.so/chm-podcast⁠Apple Podcast - ⁠https://podcasts.apple.com/us/podcast...⁠Castbox - ⁠https://castbox.fm/vh/6735434⁠Goodpods - ⁠https://goodpods.com/profile/chm-111066⁠iHeartRadio - ⁠https://iheart.com/podcast/291542082⁠Pocket Casts - ⁠https://pca.st/3ncdh11o⁠ –Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: Peer to peer interviews, panels & round-tablesCurated live events & conferencesProfessional in-depth content & research updatesInteractive learning modules & webinarsLive & on-demand webcasts & podcastsLearn more about us here - ⁠https://communityhealth.media⁠

    Dr. Neil Iyengar, Dr. Joyce O'Shaughnessy, & Dr. Ana Garrido-Castro - Evolving ADCs in 1L mTNBC

  5. Jun 25

    MATTERHORN Roundtable: Perioperative FLOT & Immunotherapy Updates in Gastric Cancer

    The treatment landscape for perioperative gastric cancer is changing rapidly. In this expert roundtable, leading GI oncology specialists discuss the practice-changing impact of the MATTERHORN trial, the role of immunotherapy in resectable gastric cancer, and how emerging data from ASCO 2026 is influencing treatment decisions in both academic and community settings. Featuring insights from Dr. Zev Wainberg, Dr. Nataliya Uboha, Dr. Sunnie Kim, Dr. Harry Menon, Dr. Angela Alistar, Dr. Raji Shameem, and Dr. Timothy Brown. Key topics discussed: MATTERHORN trial results and clinical implicationsAdding durvalumab to perioperative FLOT chemotherapyEvent-free survival and overall survival outcomesPathologic complete response (pCR) and major pathologic response (MPR)The role of PD-L1 testing and biomarker selectionInterpreting subgroup analyses in gastric cancerFLOT as the current perioperative standard of careImmunotherapy in resectable gastric and gastroesophageal cancersGlobal perspectives on gastric cancer treatmentPractical considerations for community oncologistsFuture directions in perioperative upper GI cancer research As immunotherapy moves earlier into the treatment journey, clinicians are faced with new opportunities—and new questions—about patient selection, biomarkers, treatment sequencing, and long-term outcomes. Subscribe for more expert oncology discussions, clinical trial updates, and insights from leading cancer specialists. –Thanks for watching!Our podcasts are also available on: Spotify - ⁠https://spotf.fi/chm-podcast⁠Amazon Music - ⁠https://amazn.so/chm-podcast⁠Apple Podcast - ⁠https://podcasts.apple.com/us/podcast...⁠Castbox - ⁠https://castbox.fm/vh/6735434⁠Goodpods - ⁠https://goodpods.com/profile/chm-111066⁠iHeartRadio - ⁠https://iheart.com/podcast/291542082⁠Pocket Casts - ⁠https://pca.st/3ncdh11o⁠ –Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: Peer to peer interviews, panels & round-tablesCurated live events & conferencesProfessional in-depth content & research updatesInteractive learning modules & webinarsLive & on-demand webcasts & podcastsLearn more about us here - ⁠https://communityhealth.media⁠

    MATTERHORN Roundtable: Perioperative FLOT & Immunotherapy Updates in Gastric Cancer

  6. Jun 25

    EMERALD-3 Roundtable: Hepatocellular Carcinoma Trial Breakdown & Insights

    Could EMERALD-3 redefine the treatment paradigm for unresectable hepatocellular carcinoma? In this special roundtable discussion recorded at ASCO 2026, Dr. Ghassan Abou-Alfa is joined by Dr. Gentry King, Dr. Mehmet Akce, Dr. Pierre Gholam, Dr. Lingling Du, Dr. Adam Burgoyne, Dr. Lipika Goyal, and Dr. Riad Salem to break down the landmark EMERALD-3 study. The panel explores the scientific rationale for combining transarterial chemoembolization (TACE) with immunotherapy and antiangiogenic therapy, while reviewing key efficacy findings from the EMERALD-3 study. Beyond the data, the experts discuss how locoregional therapies can enhance immune responses, and examine the practical challenges of patient selection, multidisciplinary decision-making, treatment sequencing, and the evolving role of interventional radiology in modern HCC management. Topics discussed include: EMERALD-3 trial design and resultsTACE plus systemic therapy in HCCDurvalumab and immunotherapy strategiesLenvatinib and antiangiogenic therapySynergy between embolization and immunotherapyLocoregional therapy in unresectable HCCProgression-free survival and clinical outcomesMultidisciplinary management of liver cancerInterventional radiology and oncology collaborationPatient selection for combination therapyFuture directions in hepatocellular carcinoma treatmentHow EMERALD-3 may influence clinical practiceAs treatment options continue to expand, understanding how systemic therapy and locoregional interventions work together may be key to improving outcomes for patients with liver cancer. Subscribe for more expert oncology discussions, clinical trial updates, and insights from leading cancer specialists. –Thanks for watching!Our podcasts are also available on: Spotify - ⁠https://spotf.fi/chm-podcast⁠Amazon Music - ⁠https://amazn.so/chm-podcast⁠Apple Podcast - ⁠https://podcasts.apple.com/us/podcast...⁠Castbox - ⁠https://castbox.fm/vh/6735434⁠Goodpods - ⁠https://goodpods.com/profile/chm-111066⁠iHeartRadio - ⁠https://iheart.com/podcast/291542082⁠Pocket Casts - ⁠https://pca.st/3ncdh11o⁠ –Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: Peer to peer interviews, panels & round-tablesCurated live events & conferencesProfessional in-depth content & research updatesInteractive learning modules & webinarsLive & on-demand webcasts & podcastsLearn more about us here - ⁠https://communityhealth.media⁠

    EMERALD-3 Roundtable: Hepatocellular Carcinoma Trial Breakdown & Insights

  7. Jun 25

    Dr. Ursa Brown Glaberman & Dr. Karthik Giridhar- Managing Capiva-sertib & the AKT Path-way in 2L mBC

    How are we navigating the evolving landscape of second-line treatment for metastatic HR-positive, HER2-negative breast cancer? In this full-length discussion, Dr. Ursa Brown-Glaberman and Dr. Karthik Giridhar explore one of the most rapidly evolving areas in breast oncology: treatment selection after progression on first-line endocrine therapy and CDK4/6 inhibitors. The conversation examines how molecular profiling, ctDNA testing, AKT pathway targeting,PIK3CA alterations, ESR1 mutations, and emerging biomarkers are reshaping decision-making in the second-line setting. The experts also discuss how they approach endocrine therapy sequencing, when to transition to ADCs, and how toxicity, quality of life, and patient preferences influence treatment selection. Topics discussed include: Second-line treatment strategies in HR-positive metastatic breast cancerEndocrine therapy sequencing after CDK4/6 inhibitorsESR1 mutation testing and ctDNA monitoringTissue biopsy versus liquid biopsyPIK3CA mutations and targeted therapiesCapivasertib versus alpelisib decision-makingAKT pathway inhibition in metastatic diseaseGermline BRCA and PALB2 testingBiomarker-driven treatment selectionWhen to transition from endocrine therapy to ADCsQuality of life considerations in metastatic breast cancerThe future of personalized treatment sequencing As the treatment landscape continues to expand, understanding how to personalize second-line therapy has become one of the most important challenges in modern breast cancer care. Subscribe for more expert oncology discussions, breast cancer treatment updates, and clinical insights from leading specialists. –Thanks for watching!Our podcasts are also available on: Spotify - ⁠https://spotf.fi/chm-podcast⁠Amazon Music - ⁠https://amazn.so/chm-podcast⁠Apple Podcast - ⁠https://podcasts.apple.com/us/podcast...⁠Castbox - ⁠https://castbox.fm/vh/6735434⁠Goodpods - ⁠https://goodpods.com/profile/chm-111066⁠iHeartRadio - ⁠https://iheart.com/podcast/291542082⁠Pocket Casts - ⁠https://pca.st/3ncdh11o⁠ –Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: Peer to peer interviews, panels & round-tablesCurated live events & conferencesProfessional in-depth content & research updatesInteractive learning modules & webinarsLive & on-demand webcasts & podcastsLearn more about us here - ⁠https://communityhealth.media⁠

    Dr. Ursa Brown Glaberman & Dr. Karthik Giridhar- Managing Capiva-sertib & the AKT Path-way in 2L mBC

  8. Jun 25

    Dr. Sarah Premji, Dr. Reshma Mahtani & Dr. Eleftherios Mamounas - Expanding T-DXd Across HER2 + Breast Cancer

    How is trastuzumab deruxtecan (T-DXd) reshaping treatment across early-stage and metastatic HER2-positive breast cancer? Dr. Sarah Premji, Dr. Reshma Mahtani, and Dr. Eleftherios "Terry" Mamounas discuss the practice-changing implications of DESTINY-Breast11, DESTINY-Breast05, and DESTINY-Breast09, exploring how T-DXd is moving earlier in the treatment paradigm and influencing decision-making from the neoadjuvant setting through first-line metastatic disease. The conversation examines pathologic complete response (pCR), residual disease management, toxicity monitoring, multidisciplinary care, and the evolving role of biomarkers in treatment personalization. Topics include: DESTINY-Breast11 and neoadjuvant T-DXd strategiesPathologic complete response (pCR) and treatment de-escalationResidual disease management after neoadjuvant therapyDESTINY-Breast05 and adjuvant T-DXd in high-risk diseaseMonitoring and managing interstitial lung disease (ILD)Patient education, supportive care, and toxicity mitigationMultidisciplinary collaboration in HER2-positive breast cancer careDESTINY-Breast09 and first-line metastatic treatment advancesT-DXd plus pertuzumab in metastatic HER2-positive diseaseFuture roles for ctDNA and biomarker-guided treatment decisions As HER2-directed therapies continue to evolve, clinicians are increasingly challenged to determine when to introduce the most effective treatments, how to manage long-term toxicities, and how to personalize care across the entire disease continuum. Watch more expert oncology discussions from Community Health Media and subscribe for future conversations with leading oncology experts. –Thanks for watching!Our podcasts are also available on: Spotify - ⁠https://spotf.fi/chm-podcast⁠Amazon Music - ⁠https://amazn.so/chm-podcast⁠Apple Podcast - ⁠https://podcasts.apple.com/us/podcast...⁠Castbox - ⁠https://castbox.fm/vh/6735434⁠Goodpods - ⁠https://goodpods.com/profile/chm-111066⁠iHeartRadio - ⁠https://iheart.com/podcast/291542082⁠Pocket Casts - ⁠https://pca.st/3ncdh11o⁠ –Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: Peer to peer interviews, panels & round-tablesCurated live events & conferencesProfessional in-depth content & research updatesInteractive learning modules & webinarsLive & on-demand webcasts & podcastsLearn more about us here - ⁠https://communityhealth.media⁠

    Dr. Sarah Premji, Dr. Reshma Mahtani & Dr. Eleftherios Mamounas - Expanding T-DXd Across HER2 + Breast Cancer
See All (66)

About

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences. We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcasts

Information

  • Creator
    Community Health Media
  • Years Active
    2025 - 2026
  • Episodes
    66
  • Rating
    Clean
  • Copyright
    © Community Health Media
  • Show Website
    Community Health Media